EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories, Inc.

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Licensing Agreements/Molecular diagnostics

12.08.2009

Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics
company, today announced that it signed a non-exclusive licensing
agreement for its proprietary DNA methylation biomarker Septin 9
(mSEPT9) with ARUP Laboratories, Inc. (ARUP), a provider of
diagnostic testing services based in Salt Lake City, Utah, U.S.A.

Under the agreement, ARUP has obtained rights to use the mSEPT9
biomarker to develop a molecular-based laboratory test that can help
physicians detect colorectal cancer based on a patient's blood
sample. Colorectal cancer is the second leading cause of
cancer-related deaths in the U.S.A. Epigenomics has repeatedly
demonstrated that methylated DNA of the Septin 9 gene in blood plasma
indicates the presence of colorectal cancer in early stages.

ARUP is the second commercial laboratory in the U.S.A. to
non-exclusively license the mSEPT9 biomarker from Epigenomics with
the goal of commercializing a laboratory-developed blood test for
colorectal cancer. In February 2008, Quest Diagnostics, Inc.,
Madison, New Jersey, U.S.A., already obtained a license to
commercialize a laboratory-developed test for mSEPT9 in the U.S.A.

End of Ad hoc

Further Information

For further information please see today's press release on the
Epigenomics' licensing agreement with ARUP Laboratories at
http://www.epigenomics.com/en/Newsroom/

Epigenomics legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward- looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale in the
United States. The analytical and clinical performance
characteristics of any product based on this technology which may be
sold at some future time in the U.S. have not been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade